Get 50% OFF This Summer!

Advertisement
logo

Kobo Biotech

531541
Micro Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement

Kobo Biotech Share price and Fundamental Analysis

View All Details
View All Details
Avon Organics, promoted by P R Agarwal, Rajesh Agarwal and G S Sidhu was incorporated in August 1993 to manufacture diketene and its derivatives Monomethyl Acetoncetamide(MMA) and Methyl Acetoacetate(MAA). The company's 1200 tpa Diketene manufacturing faciltiy located at Sadashivpet in Andhrapradesh and the products of it were used in pigments, pharmaceuticals and pesticides.
Company Incorporation1993
ChairmanAjit Kamath
Head QuartersMumbai
WebsiteNA
Previous NameAvon Lifesciences Ltd

Key Metrics

Market Cap (Cr)
6.48
PE Ratio
0
Industry P/E
34.33
PEG Ratio
0
ROE
3.71%
ROCE
-72.69%
ROA
-7.06%
Total Debt (Cr)
139.69
Debt to Equity
-1.05
Dividend Yield
0%
EPS
0
Book Value & P/B
-55.79 x 0
Face Value
10
Outstanding Shares(Cr)
2.38
Current Ratio
0.63
EV to Sales
0

Stock Returns

1 Week-4.23%
1 Month-12.26%
6 Months-2.86%
1 Year-41.63%
3 Years-49.06%
5 Years+24.2%

CAGR

1 Year CAGR

Revenue Growth

N/A

Net Profit Growth

N/A

Operating Profit Growth

N/A

Dividend Growth

N/A

Stock Returns CAGR

-41.63%
no_data

No Stocks

Smart Score

0.9
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Profit and Loss Statement

Credit Rating
Director Report
Chairman Report
Auditor Report
Mar 24

Promoters : 44.95%

FIIs : 0.00%

DIIs : 0.66%

Public : 54.39%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.0% of holding in March 2024 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Kobo Biotech Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Kobo Biotech Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Avon Organics, promoted by P R Agarwal, Rajesh Agarwal and G S Sidhu was incorporated in August 1993 to manufacture diketene and its derivatives Monomethyl Acetoncetamide(MMA) and Methyl Acetoacetate(MAA). The company's 1200 tpa Diketene manufacturing faciltiy located at Sadashivpet in Andhrapradesh and the products of it were used in pigments, pharmaceuticals and pesticides.

The company has a tripartite technical knowhow agreement with Shanghai Machinery & Equipment Import and Export Corporation (SMEC), representative of Shanghai Peng Pu Chemical Works (SPCW) and Xytel Technologies Partnership (XTP), US. XTP shall be the technical supervisor for the transfer of technology, while SMEC shall supply the technical knowhow.

The company has bagged the award for the Best New Product manufactured in the State of Andhra Pradesh as awarded by the Federation of Andhra Pradesh Chamber of Commerce and Industry and also certified as an ISO 9002 company by American Quality Asseassors accredited with ANSI-RAB for the manufacturing and marketing MMAA, MMAE, DEA, EEAA and Aralydes.

The company had developed technology for recovery of Diketene from sludge. The company has also diversified into Bio-Technology, where the value addition is high. To part finance its biotech project the company has made a preferential issue of 1800000 Equity shares at Rs. 38.75 each aggregating to Rs. 697.50 lacs and issued 400000 warrants convertible into 400000 equity shares during the year 1999-2000.

The Bio-Technology Plant is located at Solapur,Maharashtra for manufacture of Ephedrine and Pseudo-Ephedrine with an installed capacity of 150 MT p.a. The plant has commenced operations during April 2001. The biotech division produces Pharmaceutical intermediates i.e Pseudoephedrine and ephedrine.

The company has signed two longterm export contracts to supply fixed quantities of Pseudoephedrine and is in talks with a few more MNC's for long term contracts during the year 2001-02. The company's bio-tech division is pursuing USFD approval which will enable it to enter into regulated markets.

The company is all set to introduce two high value added intermediates in its Diketene division.The company has already completed trial production for these two pharmaceutical products and is ready for commercial launch.The company is expected an additional turnover of Rs.12 crores from these products from the year 2005-06.

Kobo Biotech Share Price

Kobo Biotech share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Kobo Biotech Market Cap

Market capitalization of Kobo Biotech indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Kobo Biotech is valued compared to its competitors.

Kobo Biotech PE Ratio

Kobo Biotech PE ratio helps investors understand what is the market value of each stock compared to Kobo Biotech 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Kobo Biotech PEG Ratio

The PEG ratio of Kobo Biotech evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Kobo Biotech ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Kobo Biotech generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Kobo Biotech ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Kobo Biotech in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Kobo Biotech Total Debt

Total debt of Kobo Biotech shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Kobo Biotech Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Kobo Biotech compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Kobo Biotech CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Kobo Biotech over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Kobo Biotech Technical Analysis

Technical analysis of Kobo Biotech helps investors get an insight into when they can enter or exit the stock. Key components of Kobo Biotech Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Kobo Biotech shares often struggle to rise above due to selling pressure.

Kobo Biotech Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Kobo Biotech ’s financial health and profitability.

Kobo Biotech Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Kobo Biotech Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Kobo Biotech Financials

The financials of Kobo Biotech provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Kobo Biotech Profit and Loss Statements

The profit and loss statement of Kobo Biotech highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Kobo Biotech .

Kobo Biotech Balance Sheet

The balance sheet presents a snapshot of Kobo Biotech ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Kobo Biotech Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App